Clinical Trial Update: First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicating the completion of a Phase 2/3 study evaluating first-line treatment for EGFR mutation-positive advanced non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Snippet

Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. | Conditions: Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 2, Phase 3 | Status: COMPLETED